European Journal of Preventive Cardiology
Obicetrapib did not raise blood sugar in pooled trials
Over 52 weeks, diabetes developed in 6.4% taking obicetrapib versus 8.5% taking placebo, but the results did not rule out no difference.Over 52 weeks, diabetes developed in 6.4% taking obicetrapib versus 8.5% taking placebo, but the results did not rule out no difference.

Randomized trial · 1,700 peopleObicetrapib
Who was studied1,700 people without diabetes, 52 weeks, against placebo
What changedAverage blood sugar did not rise with obicetrapib versus placebo; the difference was −0.02 percentage points
The catchFollow-up lasted only 52 weeks, limiting conclusions about longer-term blood sugar effects


